Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$198.86 USD

198.86
4,657,484

+2.56 (1.30%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $198.55 -0.31 (-0.16%) 7:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Sweta Killa headshot

Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs

by Sweta Killa

Though the healthcare sector is expected to post an earnings decline and has a dismal Rank, some surprises may well be in the cards, suggesting upside for healthcare ETFs.

    Zacks Equity Research

    AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store?

    by Zacks Equity Research

    AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.

      Zacks Equity Research

      Is Gilead (GILD) Poised for a Beat This Earnings Season?

      by Zacks Equity Research

      Strong performance by HIV and other antiviral products is likely to drive Gilead Sciences Inc.'s (GILD) second-quarter 2017 results.

        Zacks Equity Research

        Gilead's HCV Portfolio Receives a Boost With Vosevi Approval

        by Zacks Equity Research

        Gilead's (GILD) HCV portfolio received a boost with the FDA's approval of its once-daily HCV regimen, Vosevi.

          Zacks Equity Research

          Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?

          by Zacks Equity Research

          At Biogen's (BIIB) Q2 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in Q2.

            Zacks Equity Research

            Perrigo Company Gets FDA Approval for Generic Topical Gel

            by Zacks Equity Research

            Perrigo Company plc (PRGO) receives approval from the FDA for generic version of Androgel Topical Gel, for replacement therapy in males.

              Zacks Equity Research

              Repros' Proellex Stays on Partial Clinical Hold, Shares Fall

              by Zacks Equity Research

              Repros Therapeutics Inc. (RPRX) announced that its pipeline candidate Proellex which is being evaluated for uterine fibroids will remain on partial clinical hold.

                Zacks Equity Research

                J&J (JNJ) Gets FDA Nod for Psoriasis Drug -- Guselkumab

                by Zacks Equity Research

                Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved its pipeline candidate guselkumab for the treatment of moderate-to-severe plaque psoriasis. The drug will be marketed by the trade name of Tremfya.

                  Zacks Equity Research

                  The Zacks Analyst Blog Highlights: Boeing, AbbVie and U.S. Bancorp

                  by Zacks Equity Research

                  The Zacks Analyst Blog Highlights: Boeing, AbbVie and U.S. Bancorp

                    Zacks Equity Research

                    Can Novartis (NVS) Spring a Surprise This Earnings Season?

                    by Zacks Equity Research

                    Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report second-quarter 2017 results on Jul 18.

                      Mark Vickery headshot

                      Top Stock Reports for Boeing, AbbVie & U.S. Bancorp

                      by Mark Vickery

                      Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), AbbVie (ABBV), and U.S. Bancorp (USB).

                        Zacks Equity Research

                        Amgen Gets FDA Nod to Broaden Leukemia Drug Blincyto's Label

                        by Zacks Equity Research

                        Amgen Inc. (AMGN) announced that its supplemental biologics license application (sBLA) to convert accelerated approval for leukemia drug Blincyto to regular approval has been approved by the FDA.

                          Sweta Killa headshot

                          IPO Market Back On Track: ETFs to Tap

                          by Sweta Killa

                          After several lackluster quarters, the U.S. IPO market gained momentum in the second quarter of 2017.

                            Zacks Equity Research

                            Roche (RHHBY) Announces Positive Data on Hemophilia A Drug

                            by Zacks Equity Research

                            Roche Holdings AG (RHHBY) announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab.

                              Zacks Equity Research

                              Novartis' Cosentyx Superior to Stelara in Psoriasis Study

                              by Zacks Equity Research

                              Novartis' (NVS) psoriasis drug Cosentyx got a label update from the Committee for Medicinal Products for Human Use (CHMP) in the EU,

                                Zacks Equity Research

                                Bristol-Myers Gets FDA Nod for Orencia's Label Expansion

                                by Zacks Equity Research

                                Bristol-Myers Squibb Company (BMY) announced that the FDA has approved Orencia for treatment of adults with active psoriatic arthritis (PsA).

                                  Zacks Equity Research

                                  Galapagos-Gilead Begin Phase II Study on Uveitis Candidate

                                  by Zacks Equity Research

                                  Galapagos NV (GLPG) has announced initiation of a new phase II study, evaluating its lead pipeline candidate filgotinib for treatment of adult patients with non-infectious uveitis.

                                    Zacks Equity Research

                                    Bayer Starts Phase III Study for Uterine Fibroids' Candidate

                                    by Zacks Equity Research

                                    Bayer Aktiengesellschaft (BAYRY) announced that it has enrolled the first patient in a phase III study ASTEROID which will evaluate vilaprisan in women suffering from uterine fibroids.

                                      Zacks Equity Research

                                      Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU

                                      by Zacks Equity Research

                                      Roche (RHHBY) announced that its investigational drug polatuzumab vedot in combination with MabThera and bendamustine was granted prime status in the EU.

                                        Arpita Dutt headshot

                                        Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod

                                        by Arpita Dutt

                                        Key highlights in the biotech sector include FDA approval for Portola's (PTLA) anticoagulant and EU approval for Regeneron's rheumatoid arthritis (RA) drug.

                                          Zacks Equity Research

                                          Gilead's (GILD) HCV Drug Application Accepted in the EU

                                          by Zacks Equity Research

                                          Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.

                                            Zacks Equity Research

                                            Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti

                                            by Zacks Equity Research

                                            Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti.

                                              Zacks Equity Research

                                              AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU

                                              by Zacks Equity Research

                                              AbbVie Inc. (ABBV) announced that the CHMP of the EMA has recommended marketing approval of its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).

                                                Zacks Equity Research

                                                Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU

                                                by Zacks Equity Research

                                                Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.

                                                  Zacks Equity Research

                                                  J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study

                                                  by Zacks Equity Research

                                                  Johnson & Johnson (JNJ) announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica against Pfizer's Torisel for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).